Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Reaven’s syndrome X
- Coronary heart disease (CHD) odds ratio
- Our "toxic" lifestyle
- Landscape change in modifiable CVD risk factors
- An early finding from our lab
- Visceral obesity and metabolic abnormalities
- Risk of ischemic heart disease (IHD)
- Insulin resistance
- Simple screening tool to find insulin resistance
- Clinical identification of the metabolic syndrome
- 2009 harmonized definition of the syndrome
- Relative risks and the metabolic syndrome
- Metabolic syndrome: some issues
- Distinctions of metabolic abnormalities
- Non-obese individuals metabolic syndrome
- Waist girth among and metabolic syndrome
- Abdominal obesity and metabolic syndrome (1)
- Abdominal obesity and metabolic syndrome (2)
- Excess liver fat
- Liver fat and visceral fat: cardiometabolic risk link
- Liver fat content measurement
- Sex differences in liver fat content
- Excess visceral adiposity/liver fat data
- Visceral adipose tissue and cardiometabolic risk
- Overall objectives of INSPIRE ME IAA
- General information: INSPIRE ME IAA
- Visceral adipose tissue measurement
- Liver fat measurement (Th12-L1)
- Cardiometabolic risk
- Categorization by T2D and tertiles of VAT
- Triglyceride concentrations in men
- Triglyceride concentrations in women
- HDL cholesterol concentrations in men
- HDL cholesterol concentrations in women
- Inflammatory factors, visceral adiposity & T2D
- Liver fat, visceral adiposity & T2D
- Frequency of prevalent CVD
- Type 2 diabetes odds ratios
- Conclusion about excess visceral adiposity/liver
- Excess visceral/liver fat and high risk obesity
- Visceral obesity=dysfunctional adipose tissue?
- Visceral obesity/ectopic fat screening tool
- Hypertriglyceridemic waist
- HyperTG waist and CHD risk study
- HyperTG waist in men
- HyperTG waist in women
- Survival of hyperTG waist subgroups in men
- Survival of hyperTG waist subgroups in women
- Clinical diagnosis limitations
- Comparing CHD risk in two cases
- CHD risk associated with metabolic syndrome
- Metabolic syndrome: a component of global CMR
- Visceral adiposity/ectopic fat in risk assessment
- Management of patients with metabolic syndrome
- "Turbostatins"
- The abdominally obese patient
- More from the EPIC-Norfolk study
- CHD event rate and physical activity
- Low cardiorespiratory fitness: CHD risk factor
- Cardiorespiratory fitness predicts mortality
- Reshaping lifestyle habits of obese patients
- The “metabolic syndrome”: summary
Topics Covered
- Reaven’s syndrome X
- Coronary heart disease (CHD) and type 2 diabetes odds ratio
- Our "toxic" lifestyle
- Landscape change in modifiable CVD risk factors
- Risk of ischemic heart disease (IHD)
- Insulin resistance
- The metabolic syndrome: distinctions of metabolic abnormalities, CHD risk, non-obese individuals, waist girth, abdominal obesity and management,- Liver fat and visceral fat: cardiometabolic risk link
- Sex differences in liver fat content
- Overall objectives of INSPIRE ME IAA
- Categorization by T2D and tertiles of VAT
- Triglyceride & HDL cholesterol concentrations in men & women
- Inflammatory factors, liver fat, visceral adiposity & T2D
- Frequency of prevalent CVD
- Visceral obesity/ectopic fat screening tool
- HyperTG waist survival and CHD risk study
- Clinical diagnosis limitations
- "Turbostatins”
- The EPIC-Norfolk study
- CHD event rate and physical activity
- Reshaping lifestyle habits of obese patients
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Després, J.P. (2013, May 22). The metabolic syndrome [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 2, 2024, from https://doi.org/10.69645/IZQY9703.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Jean Pierre Després, Consultant: Novartis, Thera technologies, Torrent Pharma ; Speaker’s Bureau: Abbot, Astra Zeneca, GSK, Pfizer, Merck.
A selection of talks on Metabolism & Nutrition
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Jean-Pierre Després.
I am the Director of
Research in Cardiology
at the Quebec Heart
and Lung Institute
I am also a professor in
the Department of Medicine
at the Université Laval
in Quebec City in Canada.
Today I will address the topic
of the metabolic syndrome.
0:19
In 1988, at a landmark
lecture given
by Professor Gerald Reaven at
the annual meeting of the
American Diabetes Association,
he introduced the
notion of syndrome X,
or insulin resistance syndrome,
putting insulin resistance
as a core feature
of a constellation of
metabolic abnormalities,
increasing the risk of not only
developing type 2 diabetes,
but also cardiovascular disease.
He put forward the
hypothesis that insulin
resistance was a prevalent
metabolic abnormality,
substantially
increasing the risk of
cardiovascular disease
in our population.
0:60
As hyperinsulinemia
is one marker
of an insulin-resistant state
in a non-diabetic individual,
we examined the
relationship between
elevated fasting insulin
level and risk of
coronary disease in
our prospective data
of middle-aged men followed
after the incidence
of a first coronary
heart disease event.
In the New England Journal
of Medicine in 1996,
we reported that,
as shown on the right
panel of this figure,
that the combination of
elevated insulin levels,
characterized by the top tertile
of fasting insulin levels,
was associated with a 3.2-fold
increased risk of
coronary disease.
There was a remarkable
increase in risk
of coronary disease
associated with
the simultaneous presence of
elevated insulin levels combined
with elevated ApoB
concentration.
This duo of metabolic
abnormalities is predictive
of an 11-fold increased risk
of coronary heart disease.
Making those two abnormalities,
that are features of syndrome
X or insulin resistance,
quite atherogenic.
We need to keep in mind, again,